304 related articles for article (PubMed ID: 37692854)
1. Research progress of nanovaccine in anti-tumor immunotherapy.
Yao M; Liu X; Qian Z; Fan D; Sun X; Zhong L; Wu P
Front Oncol; 2023; 13():1211262. PubMed ID: 37692854
[TBL] [Abstract][Full Text] [Related]
2. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
[TBL] [Abstract][Full Text] [Related]
3. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
4. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
5. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
6. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
9. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy.
Thakur N; Thakur S; Chatterjee S; Das J; Sil PC
Front Chem; 2020; 8():597806. PubMed ID: 33409265
[TBL] [Abstract][Full Text] [Related]
11. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
12. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
13. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
14. Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.
Manna S; Maiti S; Shen J; Weiss A; Mulder E; Du W; Esser-Kahn AP
Biomaterials; 2023 May; 296():122062. PubMed ID: 36863071
[TBL] [Abstract][Full Text] [Related]
15. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
17. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
18. Nanomaterials: A powerful tool for tumor immunotherapy.
Chen Z; Yue Z; Wang R; Yang K; Li S
Front Immunol; 2022; 13():979469. PubMed ID: 36072591
[TBL] [Abstract][Full Text] [Related]
19. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
20. Nanomaterials: small particles show huge possibilities for cancer immunotherapy.
Chen Z; Yue Z; Yang K; Li S
J Nanobiotechnology; 2022 Nov; 20(1):484. PubMed ID: 36384524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]